PMA

(redirected from Premarket Approval)
Also found in: Medical, Acronyms.

PMA

(inorganic chemistry)
(organic chemistry)
McGraw-Hill Dictionary of Scientific & Technical Terms, 6E, Copyright © 2003 by The McGraw-Hill Companies, Inc.

PMA

(Power Matters Alliance) See AirFuel.
Copyright © 1981-2019 by The Computer Language Company Inc. All Rights reserved. THIS DEFINITION IS FOR PERSONAL USE ONLY. All other reproduction is strictly prohibited without permission from the publisher.
References in periodicals archive ?
The United States Food and Drug Administration (FDA) has granted Premarket Approval to CVRx Inc, a private medical device company, to market its BAROSTIM NEO device for heart failure in the United States, it was reported on Friday.
However, the submitted premarket approval application did not include these kinds of data.
One major difference between Class I and Class II is devices categorized as Class II have to undergo costly and time-consuming premarket approval requirements when they are modified, updated or altered--whereas manufacturers only need to notify FDA when similar changes are made to Class I devices.
For products that are already on the market, manufacturers have 30 months to comply with the premarket approval application requirements.
It explains situations in which postmarket data collection is appropriate for premarket approval (PMA) applications, both in EAP and non-EAP situations, and provides numerous examples.
"Premarket approval of the VENTANA ALK (D5F3) CDx Assay will enable more lung cancer patients to access ALK gene testing and obtain faster test results over current FISH or molecular testing methods.
Food and Drug Administration (FDA) has approved Intersect ENT's Premarket Approval (PMA) application for its Propel[TM] mometasone furoate implant, which offers localized, controlled drug delivery for patients with chronic sinusitis.
Finally, companies with less than $30 million in sales qualify for a waiver of the first PMA (premarket approval) fee.
Clinical studies in support of premarket approval applications should ideally be randomized and blinded, the agency maintained in recent draft guidance for sponsors and staff to help researchers and manufacturers design better quality clinical trials for device submissions.
In April 2010, Q-Med and its partner Oceana Therapeutics, filed a premarket approval (PMA) application for Solesta, a product for the treatment of fecal incontinence, in the USA.
The FDA recently granted approval of the Premarket Approval Application (PMA).
BioScreen participated in the analytical and microbiological portions of the submissions for FDA premarket approval. The focus of the inspection was on BioScreen's Quality Management System and compliance with FDA Good Manufacturing Practice (GMP).